Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect

Blood

Volumn 100, Issue 6, 2002, Pages 1935-1947

  Farag, Sherif S ^a,b,c   Fehniger, Todd A ^a,b   Ruggeri, Loredana ^a,b   Velardi, Andrea ^a,b   Caligiuri, Michael A ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 2; LECTIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CYTOTOXICITY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA; LIGAND BINDING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL;

EID: 0037105453     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0350     Document Type: Review

References (134)

1. Graft-versus-leukemia reactions after bone marrow transplantation
2. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
3. Prospects for adoptive T cell therapy
4. Progress in human tumour immunology and immunotherapy
5. Biology and clinical relevance of human natural killer cells
6. Biology of natural killer cells
7. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma
8. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2
9. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
10. Biology of human natural killer cell subsets
11. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2
12. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells
13. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents
14. Relationship between target cell cycle and susceptibility to natural killer lysis
15. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset
16. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors
17. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells
18. Comparative studies of human FcRIII-positive and negative natural killer cells
19. Functional heterogeneity of Leu 19"bright" + and Leu 19"dim" + lymphokine-activated killer cells
20. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF
21. Participation of the CD94 receptor complex in costimulation of human natural killer cells
22. Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin
23. Interleukin 15: Biology and relevance to human disease
24. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15
25. Regulation of the natural killer cell receptor repertoire
26. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2
27. In search of the 'missing self': MHC molecules and NK cell recognition
28. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes
29. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression
30. Skin graft rejection by beta 2-microglobulin-deficient mice
31. IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing
32. Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements
33. Activating and inhibitory NK cell receptors
34. Natural killer cell activation and inhibition by receptors for MHC class I
35. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
36. A human killer inhibitory receptor specific for HLA-A1,2
37. The natural killer cell receptor specific for HLA-A allotypes: A novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer
38. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and functional transfer
39. NKB1: A natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules
40. Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: Their role in the definition of different groups of alloreactive NK cell clones
41. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition
42. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities
43. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions
44. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells
45. Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103
46. Genomic organization of a human killer cell inhibitory receptor gene
47. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors
48. Human diversity in killer cell inhibitory receptor genes
49. NK cell receptors
50. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily
51. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells
52. Immunology of human placental implantation: Clinical implications of our current understanding
53. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors
54. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: Decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor
55. Induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells
56. Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy
57. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells
58. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules
59. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells
60. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits
61. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules
62. Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor
63. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor
64. Molecular characterization of human CD94: A type II membrane glyco-protein related to the C-type lectin superfamily
65. Natural killer lectin-like receptors have divergent carboxy-termini, distinct from Ctype lectins
66. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells
67. Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene
68. The CD94/NKG2 C-type lectin receptor complex
69. Linkage of the NKG2 and CD94 receptor genes to D12S77 in the human natural killer gene complex
70. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex
71. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody
72. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
73. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
74. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis
75. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: Preferential response to an HLA-G-derived nonamer
76. Paired inhibitory and triggering NK cell receptors for HLA class I molecules
77. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E
78. The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene
79. NK cell activation: Distinct stimulatory pathways counter-balancing inhibitory signals
80. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
81. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
82. p46, a novel natural killer cell-specific surface molecule that mediates cell activation
83. Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity
84. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis
85. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily
86. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells
87. Surface receptors delivering opposite signals regulate the function of human NK cells
88. An activating immunoreceptor complex formed by NKG2D and DAP10
89. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties
90. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA
91. MIC genes: From genetics to biology
92. Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region
93. A second lineage of mammalian major histocompatibility complex class I genes
94. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
95. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand
96. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium
97. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells
98. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of non-epithelial origin
99. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB
100. The UL16 gene of human cytomegalovirus encodes a glyco-protein that is dispensable for growth in vitro
101. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions
102. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
103. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA
104. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein
105. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes
106. CD11ac/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing
107. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction
108. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor
109. 2B4-mediated activation of human natural killer cells
110. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes
111. 2B4 functions as a co-receptor in human NK cell activation
112. Identification of NKp80, a novel triggering molecule expressed by human NK cells
113. Human KLRF1, a novel member of the killer cell lectin-like receptor gene family: Molecular characterization, genomic structure, physical mapping to the NK gene complex and expression analysis
114. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer
115. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma
116. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
117. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity
118. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - A phase II study
119. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
120. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
121. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
122. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
123. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells
124. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules
125. Effectiveness of donor natural killer call alloreactivity in mismatched hematopoietic transplants
126. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia
127. Murine natural killer cells and marrow graft rejection
128. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells
129. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice
130. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation
131. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo
132. Immunobiology of natural killer cells and bone marrow transplantation: Merging of basic and preclinical studies
133. Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones
134. The epithelial cellular associated adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR)